Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Bejar

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
RNA (New York, N.Y.)|August 6, 2016
Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulatorsJinsong Qiu, Bing Zhou, Felicitas Thol, et al.
Molecular Cancer Research : MCR|November 11, 2020
5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia CellsBrian M Reilly, Timothy Luger, Soo Park, et al.
Leukemia Research|November 18, 2016
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patientsLeylah Drusbosky, Cindy Medina, Regina Martuscello, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016
Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.
Leukemia & Lymphoma|February 7, 2020
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based surveyAlexander B Pine, Nora Chokr, Maximilian Stahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2018
Managing Clonal Hematopoiesis in Patients With Solid TumorsKelly L Bolton, Nancy K Gillis, Catherine C Coombs, et al.
Cytotherapy|December 2, 2020
In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burdenValentina Ferrari, Alison Tarke, Hannah Fields, et al.
Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.
JCO Precision Oncology|October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial IntelligenceAziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
Blood|October 3, 2015
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significanceBrian Kwok, Jeff M Hall, John S Witte, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
RNA (New York, N.Y.)|August 6, 2016
Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulatorsJinsong Qiu, Bing Zhou, Felicitas Thol, et al.
Molecular Cancer Research : MCR|November 11, 2020
5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia CellsBrian M Reilly, Timothy Luger, Soo Park, et al.
Leukemia Research|November 18, 2016
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patientsLeylah Drusbosky, Cindy Medina, Regina Martuscello, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016
Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.
Leukemia & Lymphoma|February 7, 2020
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based surveyAlexander B Pine, Nora Chokr, Maximilian Stahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2018
Managing Clonal Hematopoiesis in Patients With Solid TumorsKelly L Bolton, Nancy K Gillis, Catherine C Coombs, et al.
Cytotherapy|December 2, 2020
In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burdenValentina Ferrari, Alison Tarke, Hannah Fields, et al.
Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.
JCO Precision Oncology|October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial IntelligenceAziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
Blood|October 3, 2015
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significanceBrian Kwok, Jeff M Hall, John S Witte, et al.
Pageof 11